Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
OBJECTIVES The aim of this study was to determine the protective effect of carvedilol in anthracycline (ANT)-induced cardiomyopathy (CMP). BACKGROUND Despite its broad effectiveness, ANT therapy is associated with ANT-induced CMP. Recent animal studies and experimental observations showed that carvedilol prevented development of CMP due to chemotherapeutics. However, there is no placebo-contr...
متن کاملCarvedilol for anthracycline cardiomyopathy prevention.
alay et al. (1), in a population of apparently unselected patients eceiving their first 6 cycles of anthracyclines, found in their ontrol group a high incidence of functional cardiomyopathy: 24% f their patients had at the final examination an ejection fraction of 0% or less. This incidence of cardiac dysfunction is higher than he expected one for patients beginning their exposure to anthraycli...
متن کاملCarvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin. Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the pathogenic process. The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist ...
متن کاملEarly Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
This study tested for the benefits of early administration of carvedilol as protection against doxorubicin (DOX)-induced cardiomyopathy. Thirty male, adult B6 mice were categorized into group 1 (untreated control), group 2 [DOX treatment (15 mg/every other day for 2 weeks, i.p.], and group 3 [carvedilol (15 mg/kg/d, from day 7 after DOX treatment for 28 days)], and euthanized by day 35 after DO...
متن کاملManagement options Anthracycline-induced cardiomyopathy
Anthracycline cardiomyopathy is less frequently encountered nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for large doses to be used for certain individuals. We have demonstrated the benefit of angiotensin-co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2006
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2006.07.052